Journey Medical Corp
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a top… Read more
Journey Medical Corp (DERM) - Net Assets
Latest net assets as of September 2025: $25.90 Million USD
Based on the latest financial reports, Journey Medical Corp (DERM) has net assets worth $25.90 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($85.19 Million) and total liabilities ($59.29 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $25.90 Million |
| % of Total Assets | 30.4% |
| Annual Growth Rate | -18.41% |
| 5-Year Change | 95.0% |
| 10-Year Change | -89.18% |
| Growth Volatility | 135.83 |
Journey Medical Corp - Net Assets Trend (2014–2024)
This chart illustrates how Journey Medical Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Journey Medical Corp (2014–2024)
The table below shows the annual net assets of Journey Medical Corp from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $20.07 Million | -1.38% |
| 2023-12-31 | $20.35 Million | +19.83% |
| 2022-12-31 | $16.98 Million | -59.61% |
| 2021-12-31 | $42.04 Million | +308.50% |
| 2020-12-31 | $10.29 Million | +273.98% |
| 2019-12-31 | $2.75 Million | +130.45% |
| 2018-12-31 | $-9.04 Million | -106.04% |
| 2017-12-31 | $149.65 Million | -39.50% |
| 2016-12-31 | $247.37 Million | +33.37% |
| 2015-12-31 | $185.47 Million | +20.77% |
| 2014-12-31 | $153.58 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Journey Medical Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 437800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.01% |
| Other Components | $107.09 Million | 533.63% |
| Total Equity | $20.07 Million | 100.00% |
Journey Medical Corp Competitors by Market Cap
The table below lists competitors of Journey Medical Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
United Pharm
KO:033270
|
$126.28 Million |
|
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd
SHG:600671
|
$126.36 Million |
|
CELON PHARMA S.A. ZY-10
F:8RP
|
$126.43 Million |
|
lastminute.com N.V
PINK:LSMNF
|
$126.49 Million |
|
Cool Company Oy
OL:CLCO
|
$126.25 Million |
|
Angel Oak Mortgage Inc
NYSE:AOMR
|
$126.22 Million |
|
Carbios
PA:ALCRB
|
$126.17 Million |
|
Stereotaxis Inc
NYSE MKT:STXS
|
$126.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Journey Medical Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 20,350,000 to 20,069,000, a change of -281,000 (-1.4%).
- Net loss of 14,672,000 reduced equity.
- Other factors increased equity by 14,391,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-14.67 Million | -73.11% |
| Other Changes | $14.39 Million | +71.71% |
| Total Change | $- | -1.38% |
Book Value vs Market Value Analysis
This analysis compares Journey Medical Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.58x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.20x to 7.58x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $6.23 | $7.45 | x |
| 2015-12-31 | $6.94 | $7.45 | x |
| 2016-12-31 | $7.49 | $7.45 | x |
| 2017-12-31 | $3.69 | $7.45 | x |
| 2018-12-31 | $-0.22 | $7.45 | x |
| 2019-12-31 | $0.17 | $7.45 | x |
| 2020-12-31 | $0.62 | $7.45 | x |
| 2021-12-31 | $2.43 | $7.45 | x |
| 2022-12-31 | $0.97 | $7.45 | x |
| 2023-12-31 | $1.12 | $7.45 | x |
| 2024-12-31 | $0.98 | $7.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Journey Medical Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -73.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -26.14%
- • Asset Turnover: 0.70x
- • Equity Multiplier: 4.00x
- Recent ROE (-73.11%) is below the historical average (-44.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -20.75% | -436.64% | 0.04x | 1.16x | $-47.23 Million |
| 2015 | -42.27% | -1073.96% | 0.03x | 1.20x | $-96.95 Million |
| 2016 | -36.01% | -394.44% | 0.07x | 1.26x | $-113.82 Million |
| 2017 | -202.65% | -6678.29% | 0.01x | 3.75x | $-318.23 Million |
| 2018 | 0.00% | -523.25% | 0.12x | 0.00x | $-220.64 Million |
| 2019 | 131.72% | 10.38% | 1.03x | 12.30x | $3.35 Million |
| 2020 | 51.33% | 11.86% | 0.86x | 5.04x | $4.25 Million |
| 2021 | -104.64% | -69.68% | 0.65x | 2.31x | $-48.20 Million |
| 2022 | -174.47% | -40.22% | 0.70x | 6.19x | $-31.33 Million |
| 2023 | -18.93% | -4.87% | 1.03x | 3.78x | $-5.89 Million |
| 2024 | -73.11% | -26.14% | 0.70x | 4.00x | $-16.68 Million |
Industry Comparison
This section compares Journey Medical Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $580,491,146
- Average return on equity (ROE) among peers: -45.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Journey Medical Corp (DERM) | $25.90 Million | -20.75% | 2.29x | $126.26 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $14.78 Million | -64.19% | 0.99x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-241.47K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -329.21% | 0.78x | $194.64 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $37.06 Million | 39.05% | 0.16x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $32.70 Million | -18.88% | 0.16x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.84 |
| Adcock Ingram Holdings Limited (AIHLF) | $4.54 Billion | 14.90% | 0.58x | $85.61 Million |